Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that it has entered into a research collaboration with AbCellera for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. Confo will apply its proprietary ConfoBody technology to stabilize the selected GPCRs in their disease-relevant conformations, which will then be used as antigens to enable antibody discovery and development. Confo will be entitled to upfront payments, milestones, and tiered royalties on net product sales.
“We are thrilled to start this collaboration with AbCellera to discover the best-possible antibody candidates against two challenging GPCR targets. This serves as an additional validation recognizing the power of Confo’s platform and our ability to overcome the limitations of GPCR antibody discovery,” said Cedric Ververken, CEO of Confo Therapeutics. “Entering into select, high-value collaborations allows us to efficiently deploy our platform together with leading companies while we continue to build out our own pipeline of innovative and impactful medicines.”
